Pipeline

Virogin is dedicated to bringing next-generation immuno-oncology therapeutics to the clinic through our robust pipeline.

Oncolytic Virus (Attenuated & Non-attenuated Viral Backbone)

Backbone

ID#

Indications

PHASE

Discovery

IND-Enabling

Phase I

Phase II

Phase III

Commercial

Virogin rights

Attenuated

ID#:

VG161*
(I.T)

Indications:

HCC, ICC, etc.

HCC, ICC, etc.

Phase:

Virogin Rights:

Worldwide excluding Greater China

Transcription & Translation
Dual Regulation (TTDR)

ID#:

VG201
(I.V)

Indications:

Solid Tumors

Solid Tumors

Phase:

Virogin Rights:

Worldwide

ID#:

VG201
(I.T)

Indications:

Solid Tumors

Solid Tumors

Phase:

Virogin Rights:

Worldwide

ID#:

VG203

Indications:

Solid Tumors

Solid Tumors

Phase:

Virogin Rights:

Worldwide

ID#:

VG302

Indications:

Solid Tumors

Solid Tumors

Phase:

Virogin Rights:

Worldwide

mRNA Vaccines and Therapeutics (Conventional mRNA & Self-amplifying RNA)

ID#

Potential Indications

PHASE

Discovery

IND-Enabling

Phase I

Phase II

Phase III

Commercial

Virogin rights

ID#:

Monkeypox mRNA vaccine

Potential Indications:

Monkeypox

Monkeypox

Phase

Virogin Rights:

Worldwide

ID#:

HPV (Human papilloma virus)

Potential Indications:

HPV16- associated skin lesions, HPV16+ cancer, HSIL

HPV16- associated skin lesions, HPV16+ cancer, HSIL

Phase

Virogin Rights:

Worldwide

ID#:

HER2 mRNA vaccine

Potential Indications:

HER2+ tumors

HER2+ tumors

Phase

Virogin Rights:

Worldwide

ID#:

EBV (Epstein-Barr virus) mRNA vaccine

Potential Indications:

EBV+ tumors

EBV+ tumors

Phase

Virogin Rights:

Worldwide

*VG161 to be developed for the Greater China market in partnership with CNBG, a Sinopharm subsidiary (Virogin Biotech retains worldwide rights excluding Greater China);

i.t= intratumoral; i.v= intravenous